Andrx to Present at XIV International Symposium on Drugs Affecting Lipid Metabolism.Business Editors/Health & Medical Writers FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Sept. 6, 2001 ANDRX CORPORATION - Andrx Group (Nasdaq:ADRX ADRX Andrx Corporation (stock symbol) ) today announced that it will be presenting at the XIV International Symposium on Drugs Affecting Lipid Metabolism (DALM DALM Dysplasia-associated lesion/mass GI disease An acronym referring to ↑ incidence of colorectal CA with ulcerative colitis when the pathologist finds dysplasia and the endoscopist finds a tumor mass; DALM alone may be a sufficient criterion for ). Sponsored by the Giovanni Lorenzini Medical Foundation in Houston, Texas, the symposium will be held September 9 - 12, 2001, at the New York Hilton and Towers in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . The Andrx presentation will detail the results of three lipid efficacy, safety and metabolism studies: Comparative Pharmacokinetics of Lovastatin lovastatin /lo·va·stat·in/ (lo´vah-stat?in) an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used in the treatment of hypercholesterolemia and other forms of dyslipidemia and to lower the risks associated with Extended-Release Tablets and Lovastatin Immediate-Release Tablets in Humans; A Multiple-Dose Safety, Pharmacokinetic and Pharmacodynamic Study of Lovastatin Extended-Release Relative to Lovastatin Immediate-Release; and A Dose-Response, Safety and Efficacy Study of an Extended-Release Form of Lovastatin in Adult Patients with Hypercholesterolemia Hypercholesterolemia Definition Hypercholesterolemia refers to levels of cholesterol in the blood that are higher than normal. Description Cholesterol circulates in the blood stream. It is an essential molecule for the human body. . In addition, Andrx's Executive Vice President of Research and Development of its branded product efforts, Lawrence T. Friedhoff, M.D., Ph.D., will deliver an oral presentation entitled "Controlled-Release Lovastatin Reduced Human Beta-Amyloid and LDL-Cholesterol in a Double-Blind Placebo-Controlled Clinical Study" at a session entitled, "Lipid Lowering Drugs: Clinical Studies" on Monday, September 10, 2001, between 2:00 - 4:00 PM EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT . Andrx Corporation is a specialty pharmaceutical company engaged in the formulation and commercialization of oral controlled-release generic and brand pharmaceuticals utilizing its proprietary drug delivery technologies. This release and additional information about Andrx Corporation are also available on the Internet at: http://www.andrx.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion